Comment
doi: 10.1024/1661-8157.98.3.131.
[Comment from the family practice viewpoint]
[Article in
German]
Affiliations
- PMID: 19180439
- DOI: 10.1024/1661-8157.98.3.131
Item in Clipboard
Comment
[Comment from the family practice viewpoint]
[Article in
German]
Praxis (Bern 1994).
.
No abstract available
Comment on
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9. N Engl J Med. 2008. PMID: 18997196 Clinical Trial.
Similar articles
-
[Comment from the lipidologic viewpoint].Praxis (Bern 1994). 2009 Feb 4;98(3):125-7. doi: 10.1024/1661-8157.98.3.125. Praxis (Bern 1994). 2009. PMID: 19180437 German. No abstract available.
-
[Comment from the cardiologic viewpoint].Praxis (Bern 1994). 2009 Feb 4;98(3):129-30. doi: 10.1024/1661-8157.98.3.129. Praxis (Bern 1994). 2009. PMID: 19180438 German. No abstract available.
-
The JUPITER Trial: responding to the critics.Am J Cardiol. 2010 Nov 1;106(9):1351-6. doi: 10.1016/j.amjcard.2010.08.025. Epub 2010 Sep 21. Am J Cardiol. 2010. PMID: 21029837 No abstract available.
-
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.Circulation. 2003 Nov 11;108(19):2292-7. doi: 10.1161/01.CIR.0000100688.17280.E6. Circulation. 2003. PMID: 14609996 Review. No abstract available.
-
Lipid lowering for primary prevention.Lancet. 2009 Apr 4;373(9670):1152-5. doi: 10.1016/S0140-6736(09)60357-3. Lancet. 2009. PMID: 19345816 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
